see the future of treatment

who we are

About Théa Pharma Inc.

Théa Pharma Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products in the United States.

Established in 2019, Théa Pharma is the U.S. subsidiary of Laboratoires Théa, a global leader and pioneer in ophthalmology. We are committed to supporting doctors that treat all conditions for anterior and posterior segments, along with ocular surface conditions.

Advancing the Future of Eye Care

Building on its 150-year legacy in eye care, Théa is expanding its commitment to ophthalmology by advancing into the retina space. Building on its pioneering work in preservative-free topical formulations, Théa is extending its innovation to address serious retinal diseases.

Théa is advancing Phase 2 and Phase 3 clinical programs, including the investigation of RNA-based therapies for inherited retinal diseases such as Leber congenital amaurosis type 10 (LCA10) and Usher syndrome type 2A. The company is also partnering to develop potential treatments for geographic atrophy and retinitis pigmentosa. An important upcoming milestone is the anticipated 2027 launch of Cyklx™ (articaine ophthalmic solution) 8%.

Our mission is to deliver uncompromising eye care and empower all stakeholders to envision the future of ophthalmic treatment with eyes wide open.

Together, we can build a future filled with better outcomes.